A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta

Objective: To evaluate the efficacy and safety of combination therapy with pulse cyclophosphamide given with methylprednisolone (MP) and interferon beta (IFNβ)-1a in multiple sclerosis (MS) patients with active disease during IFNβ monotherapy. Methods: This was a randomized, single-blind, parallel-group, multicenter trial in MS patients with a history of active disease during IFNβ treatment. Patients were randomized to either cyclophosphamide 800 mg/m2 plus methylprednisolone 1 g IV (CY/MP) or methylprednisolone once a month for six months and then followed for an additional 18 months. All patients received three days of methylprednisolone 1 g IV at screening and 30 mcg IFNβ-1a IM weekly for the entire 24 months. The primary endpoint was change from baseline in the mean number of gadolinium-enhancing (Gd+) lesions. Secondary clinical endpoints included time to treatment failure. Results: Fifty-nine patients were randomized to treatment: 30 to CY/MP and 29 to MP. Change from baseline in the number of Gd+ lesions was significantly different between treatment groups at three (P=0.01), six (P=0.04) and 12 months (P=0.02), with fewer lesions in the CY/MP group. The cumulative rate of treatment failure was significantly lower in the CY/MP group compared with the MP group (rate ratio =0.30; 95% confidence interval, 0.12-0.75; P=0.011). CY/MP treatment was well tolerated. Conclusion: Combination therapy with CY/MP and IFNβ-1a decreased the number of Gd+ lesions and slowed clinical activity in patients with previously active disease on IFNβ alone.

[1]  P. Clark,et al.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[2]  H. Kornhuber,et al.  Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone , 1995, Neuroradiology.

[3]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[4]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[5]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[6]  H. Weiner,et al.  Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis , 2002, Multiple sclerosis.

[7]  H. Weiner,et al.  Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects , 2002, Multiple sclerosis.

[8]  K. Zou,et al.  Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy , 2002, Journal of magnetic resonance imaging : JMRI.

[9]  R. Rudick,et al.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.

[10]  F. Nicoletti,et al.  Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis , 2001, Journal of neurology, neurosurgery, and psychiatry.

[11]  G. Illei,et al.  Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis , 2001, Annals of Internal Medicine.

[12]  D. Bever,et al.  PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS , 2001, Neurology.

[13]  O. Khan,et al.  Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy , 2001, Multiple sclerosis.

[14]  Ron Kikinis,et al.  Adaptive, template moderated, spatially varying statistical classification , 2000, Medical Image Anal..

[15]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[16]  M. Gobbini,et al.  Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis , 1999, Journal of Neuroimmunology.

[17]  R. Killiany,et al.  Quantitative follow‐up of patients with multiple sclerosis using MRI: Reproducibility , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[19]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[20]  H. Weiner,et al.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. , 1998, The Journal of clinical investigation.

[21]  H. Weiner,et al.  Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. , 1998, Clinical immunology and immunopathology.

[22]  Burden of Illness of Multiple Sclerosis: Part I: Cost of Illness , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  M Rovaris,et al.  Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis , 1997, Neurology.

[24]  H. Weiner,et al.  Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia , 1997, Annals of neurology.

[25]  R. Kinkel,et al.  TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE , 1997 .

[26]  E. Cabanis,et al.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[27]  L. Wilkins.  Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.

[28]  A. Steinberg,et al.  Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis , 1996, Annals of Internal Medicine.

[29]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[30]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[31]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[32]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[33]  A. Thompson,et al.  Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration , 1992, Neurology.

[34]  B. Fireman,et al.  Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[35]  T. A. S. Group.  The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis , 1991, The Lancet.

[36]  H. Weiner,et al.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.